Sepracor

Sepracor, Inc. nasdaq: SEPR is a pharmaceutical company founded in 1984 and located in Marlborough, Massachusetts. The company's primary focus is on products for the treatment of central nervous system and respiratory disorders. The primary source of its revenue is the approximately $600 million annually from its Xopenex franchise of drugs, available as a multi-dose inhaler (MDI) or nebulized (UDV) form. However, the blockbuster insomnia drug Lunesta, which was approved by the FDA in December, 2004 and launched in April of 2005, is on pace to exceed $1 billion in annual sales. In addition, on February 13, 2006, Sepracor filed a new drug application (NDA) for Brovana to treat Chronic Obstructive Pulmonary Disease (COPD).

Acadia Pharmaceuticals
On January 10, 2005, Sepracor partnered to advance a joint muscarinic-1 receptor agonist program for neuropathic pain.

Schering-Plough
In December of 1997 Schering-Plough obtained exclusive worldwide rights to Sepracor's patents relating to desloratadine. In January 2002, Schering-Plough launched the product as Clarinex® for the treatment of seasonal allergic rhinitis (SAR).

Sanofi-Aventis
Sepracor earns royalties from patents relating to fexofenadine which is marketed as Allegra® by Sanofi-Aventis. Fexofenadine is a nonsedating antihistamine for the treatment of allergic rhinitis. In December of 1993, Sepracor licensed the United States patent for the use of fexofenadine to Hoechst Marion Roussel (HMRI). HMRI developed the drug and launched it in late 1996 as Allegra brand fexofenadine hydrochloride.

Sepracor Canada Ltd.
Sepracor Canada Ltd. is a 38,000 square foot facility located in Windsor, Nova Scotia, Canada. Sepracor Canada is a pilot and commercial plant operation and the commercial manufacturing site for levalbuterol HCl, the active ingredient in XOPENEX®, and eszopiclone, the active ingredient in LUNESTA®, since launch.

GlaxoSmithKline
On September 11, 2007, Sepracor signed a marketing deal with British pharmaceutical company GlaxoSmithKline over the rights to sell Lunesta in Europe. If all stipulations are met, Sepracor is expected to receive approximately 155 million dollars in compensation for supplying the drug. Currently, Lunesta, known as Lunivia in Europe, is under review by the European Union's equivalent of the U.S. Food and Drug Administration for regulatory purposes.